Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865952 | 0.91 | AR (0.66) | ARPGRNR3C1 | |
| SCHEMBL2858704 | 0.88 | AR (0.66) | ARPGRNR3C1 | |
| SCHEMBL2868949 | 0.87 | AR (0.68) | ARPGRNR3C1 | |
| SCHEMBL2864168 | 0.78 | AR (0.66) | ARPGRNR3C1 | |
| SCHEMBL2863333 | 0.73 | AR (0.64) | ARPGRNR3C1 | |
| SCHEMBL2867083 | 0.72 | AR (0.90) | ARPGRNR3C1 | |
| SCHEMBL3018996 | 0.71 | AR (1.00) | ARPGRNR3C1 | |
| SCHEMBL2869873 | 0.71 | AR (0.66) | ARPGRNR3C1 | |
| SCHEMBL5130073 | 0.71 | AR (1.00) | ARPGRNR3C1 | |
| SCHEMBL7693387 | 0.71 | AR (1.00) | ARPGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | claimed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | claimed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | claimed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | claimed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | claimed |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-08-19 | — | — | US | disclosed |
| US-7727980-B2 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | ZHI LIN | 2006-06-15 | — | — | US | disclosed |
| US-7026484-B2 | For therapy of cancer | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1363909-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2002-12-05 | — | — | US | disclosed |
| WO-2002066475-A2 | TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183346-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C1 34/4885 |
| US-20070293528-A9 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C1 34/4885 |
| US-20100210678-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 46/4885NR3C1 28/4885 |
| US-20060128740-A1 | Tricyclic androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885PGR 42/4885NR3C1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.